• FDA Grants Arvinas’ ARV-110 Fast Track Designation for mCRPC
  • Most Prostate Cancer Patients on Active Surveillance Don’t Follow Monitoring Guidelines, Study Shows
  • Study Shows How Prostate Cancer Cells Mimic Bone When They Metastasize
  • Darolutamide/ADT Combo Delays Disease Worsening in Some PC, Phase 3 Trial Shows
  • Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
  • Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives
  • American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer
  • Patient Survey Sheds Light on Emotional and Overall Impact of Prostate Cancer
  • RB1 Mutations Linked to Worse Outcomes in Prostate Cancer Patients, Study Finds
  • Prostate Cancer Foundation Puts Patients on Path to Knowledge with Updated Guide, Resources
  • Xtandi Extends Time to Disease Worsening in Certain Metastatic Prostate Cancer Patients – Without Added Side Effects – Study Shows
  • Xtandi Better, Cheaper than Zytiga for Treatment of mCRPC, Study Suggests